NRG vs DYN vs VST vs SRPT vs BMRN

For growth investors, Sarepta Therapeutics, Inc.

(SRPT) is the stronger pick with 15. 6% revenue growth year-over-year, versus -12. 4% for Vistra Corp. (VST). BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 30. 0x trailing P/E (13. 6x forward), making it the more compelling value choice. Analysts rate NRG Energy, Inc. (NRG) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, BioMarin Pharmaceutical Inc.

(BMRN) is the cheapest at 30. 0x versus Vistra Corp. at 66. 8x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: NRG Energy, Inc. wins at 1. 03x versus Vistra Corp. 's 1. 49x — a reasonable growth-adjusted valuation.

Over the past 5 years, Vistra Corp.

(VST) delivered a total return of +847. 6%, compared to -71. 5% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: VST returned +901. 5% versus BMRN's -35. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 64β versus Dyne Therapeutics, Inc. 's 2. 27β — meaning DYN is approximately 258% more volatile than BMRN relative to the S&P 500. On balance sheet safety, Dyne Therapeutics, Inc. (DYN) carries a lower debt/equity ratio of 2% versus 10% for NRG Energy, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sarepta Therapeutics, Inc.

(SRPT) is pulling ahead at 15. 6% versus -12. 4% for Vistra Corp. (VST). On earnings-per-share growth, the picture is similar: Dyne Therapeutics, Inc. grew EPS -3. 0% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioMarin Pharmaceutical Inc.

(BMRN) is the more profitable company, earning 10. 8% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — BMRN leads at 77. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, NRG Energy, Inc. (NRG) is the more undervalued stock at a PEG of 1. 03x versus Vistra Corp. 's 1. 49x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Sarepta Therapeutics, Inc. (SRPT) trades at 5. 9x forward P/E versus 16. 7x for Vistra Corp. — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DYN: 113. 5% to $37. 60.

In this comparison, NRG (1.

5% yield), VST (0. 6% yield) pay a dividend. DYN, SRPT, BMRN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vistra Corp.

(VST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 6% yield, +901. 5% 10Y return). Dyne Therapeutics, Inc. (DYN) carries a higher beta of 2. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VST: +901. 5%, DYN: -26. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NRG (Utilities) and DYN (Healthcare) and VST (Utilities) and SRPT (Healthcare) and BMRN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NRG is a mid-cap quality compounder stock; DYN is a small-cap quality compounder stock; VST is a mid-cap quality compounder stock; SRPT is a small-cap high-growth stock; BMRN is a mid-cap quality compounder stock. NRG, VST pay a dividend while DYN, SRPT, BMRN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.